According to the findings of a single-center retrospective analysis, novel oral anticoagulants (NOACs) are effective and safe in adults with congenital heart disease (ACHD). This study was carried out to investigate ACHD patients (median age 55 years, 57% were male) who had been receiving NOAC treatment for a minimum of three months.

The median follow-up period was seventeen months (interquartile range [IQR]: 10–41). The most popular used NOAC was Eliquis (47% usage). HAS-BLED was 1 (IQR: 0–2) and the median CHA2DS2-VASc score was 2 (IQR: 0-3). Among the patients, 27% had complex ACHD. During the 64 years of cumulative patient follow-up, no thromboembolic events were documented. However, one significant unspecified hemorrhage was noted. Hence, the use of NOACs is safe and efficient in ACHD-affected people. It is crucial to carry out more extensive research on NOAC use in ACHD patients.